You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 8, 2025

Claims for Patent: 10,385,067

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,385,067

Title:	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- zepin-8-olate
Abstract:	The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,- 13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-- 8-olate Form I, pharmaceutical formulations, and uses thereof for treating or prophylactically preventing an HIV infection.
Inventor(s):	Carra; Ernest A. (Foster City, CA), Chen; Irene (San Mateo, CA), Zia; Vahid (Palo Alto, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	15/624,166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,385,067
Patent Claims:	1. A method for treating an HIV infection in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound of Formula II: ##STR00004## which is crystalline and is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at about 5.5.degree., 16.1.degree., and 23.3.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 2. The method of claim 1, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 22.1.degree., and 28.5.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 3. The method of claim 2, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 22.5 and 19.5.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 4. The method of claim 3, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 26.6.degree. and 17.9.degree. 2-.theta..+-.0.2.degree. 2-.theta.. 5. The method of claim 1, wherein the compound of Formula II is characterized by an x-ray powder diffraction (XRPD) pattern substantially as set forth in FIG. 1. 6. The method of claim 1, wherein the compound of Formula II is characterized by differential scanning calorimetry (DSC) pattern substantially as set forth in FIG. 2. 7. The method of claim 1, wherein the compound of Formula II is characterized by a dynamic vapor sorption (DVS) pattern substantially as set forth in FIG. 4. 8. The method of any one of claims 1 and 2 to 7, wherein the compound of Formula II is characterized by being partially or fully hydrated. 9. The method of any one of claims 1 and 2 to 7, wherein the compound of Formula II is characterized by being anhydrous or essentially anhydrous. 10. A method for treating an HIV infection in a human in need thereof, comprising administering to the human a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II: ##STR00005## which is crystalline and is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at about 5.5.degree., 16.1.degree., and 23.3.degree. 2-.theta..+-.0.2.degree..+-.2-.theta., and a pharmaceutically acceptable carrier or excipient. 11. The method of claim 10, wherein the pharmaceutical composition further comprises one to three additional therapeutic agents. 12. The method of claim 11, wherein the additional therapeutic agents are each anti-HIV drugs. 13. The method of claim 11, wherein the additional therapeutic agents are each independently selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, pharmacokinetic enhancers, and other drugs for treating HIV. 14. The method of claim 11, wherein one of the one to three additional therapeutic agents is an HIV nucleoside inhibitor of reverse transcriptase. 15. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir disoproxil fumarate and emtricitabine. 16. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir alafenamide and emtricitabine. 17. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir alafenamide hemifumarate and emtricitabine. 18. The method of any one of claims 10 to 17, wherein the pharmaceutical composition is in a unit dosage form. 19. The method of claim 18, wherein the unit dosage form is a tablet.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.